Our review provides context to clinicians regarding the use of GLP1-RA drugs in patients with or at risk of DKD to reduce UACR and help prevent adverse renal outcomes or the precipitation of ESRD in patients with T2 DM. Here, GLP1R is linked to diabetic kidney disease.